)
Milestone Pharmaceuticals (MIST) investor relations material
Milestone Pharmaceuticals TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Product overview and market need
CARDAMYST (etripamil) approved December 12, now commercially launched for PSVT, available in pharmacies since January, with full commercial and marketing efforts underway.
PSVT affects over 2 million in the US, with 200,000–300,000 new diagnoses annually; half of patients are commercially insured, aiding launch strategy.
Existing acute treatments are limited; CARDAMYST offers a portable, on-demand nasal spray with rapid onset and robust clinical data.
No branded competition exists, and the product is protected by patents through 2042.
Commercialization strategy and launch execution
Focused on 10,000 high-volume HCPs treating 500,000 actively managed patients, using a 60-rep sales force.
Retail distribution in 50,000 US pharmacies, with patient and HCP support programs to ease prescribing and access.
Pricing set at $1,649 WAC, with co-pay mitigation to $25 for commercial patients and strategies to secure tier 2/3 coverage.
Early launch metrics show scripts are building weekly, with all support systems functioning as planned.
Main physician pushback is lack of awareness; once informed, adoption is expected to accelerate due to familiarity with drug class.
Financials and future pipeline
Recent cash balance bolstered by a $75M royalty payment; updated financials to be released with the 10-K.
Planning a Phase III trial for atrial fibrillation, targeting a market 3–4 times larger than PSVT, with a 2-year study timeline.
Phase II AFib data showed rapid, durable ventricular rate reduction and reduced need for IV/oral meds.
Ex-US expansion will be pursued via partnerships; a Greater China partner is in regulatory review following a successful Phase III.
Next Milestone Pharmaceuticals earnings date
Next Milestone Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage